CRAIG DENNY: Open Payments
NPI 1720071319 · IDAHO FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,008 in 97 payments from 14 companies in 2025. Trend: 2023 $1,523 · 2024 $2,029 · 2025 $2,008
Food & beverage: $1,937Education: $71
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $491 |
| ABBVIE INC. | 21 | $393 |
| Teva Pharmaceuticals USA, Inc. | 7 | $210 |
| Vanda Pharmaceuticals Inc. | 9 | $207 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Neurocrine BioSciences, Inc. | 5 | $101 |
| Lundbeck LLC | 4 | $75 |
| Supernus Pharmaceuticals, Inc. | 4 | $74 |
| Alkermes, Inc. | 3 | $65 |
Products named: CAPLYTA, VRAYLAR, FANAPT, REXULTI, Auvelity, AUSTEDO XR, INGREZZA, Qelbree.
Industry payments across ID — which companies pay providers there.
